Acquisition

Emcure Ref: EPL/CS/SE/0054/2026 Date: July 03, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai - 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition/ investment in step-down subsidiary by subsidiary Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”) and in furtherance to the disclosure made in the Prospectus filed with the Securities Exchange Board of India, during the Initial Public Offer of the Company, we wish to inform you that Marcan Pharmaceuticals Inc., a subsidiary of the Company (“Marcan”) has on July 02, 2026 (EDT) entered into share purchase agreements with certain shareholders of Mantra Pharma Inc., a step-down subsidiary of the Company (“Mantra”), to acquire all of Class E Special Shares in the share capital of Mantra. Consequently, Mantra continues to be 100% subsidiary of Marcan. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the LODR Regulations are provided in Annexure A, enclosed herewith. The intimation is being made within reasonable time upon occurrence of the event, taking into account the applicable time-zone difference. You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary and Compliance Officer Membership No.: A25687 Encl: As above Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure Annexure A Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015: Sr. No Particulars Information a) Name of the target entity, details Mantra Pharma Inc., a company incorporated in brief such as size, turnover etc. under the laws of Quebec, Canada (“Mantra”). Mantra is engaged in the marketing and distribution of prescription drugs and natural health products. Annual Turnover: CAD $ 96.67 million Market: Canada Capital Structure: The issued, subscribed and paid up share capital is 1,000 Class A Common Shares and 24,000,000 Class E Special Shares without par value. b) Whether the acquisition would The acquisition (by subsidiary into step-down fall within related party subsidiary) constitutes a related party transaction(s) and whether the transaction between two wholly-owned promoter/ promoter group/ subsidiaries, exempted under Regulation 23(5) group companies have any of LODR Regulations. The transaction shall be interest in the entity being undertaken at arm’s length basis. acquired? If yes, nature of interest and details thereof and whether Except as step-down subsidiary of the the same is done at “arm’s length” Company, the promoter / promoter group/ group companies of the Company do not have any interest in Mantra. c) Industry to which the entity being Pharmaceuticals acquired belongs d) Objects and impacts of acquisition In accordance with the terms of the Preferred (including but not limited to, Share Purchase Agreements entered into during disclosure of reasons for the acquisition of Mantra as described in point ‘j’ acquisition of target entity, if its below, Marcan is purchasing all of the Preferred business is outside the main line of shares i.e., Class E Special Shares from certain business of the listed entity) shareholders of Mantra. Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure e) Brief details of any governmental The acquisition is subject to completion of or regulatory approvals required requisite compliances in accordance with for the acquisition applicable laws in Canada. No specific government approvals are required. f) Indicative time period for On July 03, 2026 completion of the acquisition g) Nature of consideration - whether Cash Consideration cash consideration or share swap and details of the same h) Cost of acquisition or the price at An aggregate consideration of which the shares are acquired CAD $ 50 million. i) Percentage of shareholding/ 100% of Class E Special Shares control acquired and/ or number of shares acquired j) Brief background about the entity Mantra, a wholly owned subsidiary of Marcan acquired in terms of products/line Pharmaceuticals Inc. (“Marcan”) was formed on of business acquired, date of November 06, 2023 under the Business incorporation, history of last 3 Corporation Act (Quebec) by amalgamation years turnover, country in which between 9501-2969 Québec Inc. (a company the acquired entity has presence incorporated and capitalized by Marcan on and any other significant October 16, 2023), Mantra Pharma Inc. (erstwhile information (in brief) Mantra), Myriad Pharma Inc., Mantra Distribution Inc., Holding JFL Inc., Gestion Nirdac Inc., Gestion Stéphane Turcotte Inc., Gestion Beflan Inc. and Gestion Éléoraph Inc. The company operates primarily in the Canadian market. The aggregate historical turnover for the last three financial years is approximately: Financial Year 2026: CAD $ 96.67 million Financial Year 2025: CAD $ 81.01 million Financial Year 2024: CAD $ 28.26 million* *For the period November 06, 2023 till March 31, 2024. Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251